CD19 and neoplasm: What needs to be considered is whether the normal cell can be depleted with acceptable toxicity, such as CD19 CAR-T cell therapy, which results in B cell aplasia [37], or whether expression is drastically higher on tumor cells, thus favoring tumor cell killing with limited healthy tissue OTOT, such as GD2 CAR-T cells [38].